Acorda Therapeutics is an American biopharmaceutical company focused on the development and commercialization of therapies for neurological disorders. Headquartered in Ardsley, New York, the company was founded in 1995 and has primarily concentrated its efforts on addressing unmet medical needs for people with conditions such as multiple sclerosis (MS) and Parkinson's disease.
History Acorda Therapeutics was established with a mission to develop innovative treatments for central nervous system disorders. The company's early research efforts centered on remyelination and neuronal protection. Over the years, Acorda has grown through both internal drug development and strategic acquisitions, leading to the approval of several key products.
Key Products and Therapies
- Ampyra (dalfampridine extended-release tablets): This is Acorda's most well-known product, approved by the U.S. Food and Drug Administration (FDA) in 2010. Ampyra is indicated to improve walking in adults with multiple sclerosis (MS). It works by blocking potassium channels, which is thought to improve nerve signal conduction in demyelinated axons. The drug is also known as Fampyra in some international markets, where it is licensed to Biogen.
- Inbrija (levodopa inhalation powder): Approved by the FDA in 2018, Inbrija is an inhaled formulation of levodopa designed for the intermittent treatment of "off" episodes (periods of decreased mobility, increased tremor, and muscle stiffness) in people with Parkinson's disease receiving a carbidopa/levodopa regimen. It provides a rapid-acting option for managing these sudden symptom fluctuations.
Research and Development Historically, Acorda's pipeline has explored various compounds for neurological conditions, including spinal cord injury, post-stroke deficits, and other neurodegenerative diseases. While the company has refined its focus over time, its commitment remains on developing treatments that can significantly impact the lives of patients with challenging neurological conditions.
Corporate Status Acorda Therapeutics has navigated a dynamic landscape within the biopharmaceutical industry, facing challenges related to patent litigation, competition, and financial restructuring. Despite these complexities, the company continues to operate with its approved products, focusing on patient access and support programs.